No evidence of amplified Plasmodium falciparum plasmepsin II gene copy number in an area with artemisinin-resistant malaria along the China–Myanmar border

Table 2 Outcome of the therapeutic efficacy study of DHA-PPQ treatment of uncomplicated P. falciparum from 2010 to 2014

Year	Sites	Day 3 + (%)	ACPR (%)	LCF (%)	LPF (%)	ETF (%)	WTH/LFU (%)
2010^c	Yingjiang	5.9% (1/29)	100.0% (20/20)	0.0% (0/20)	0.0% (0/20)	0.0% (0/20)	31.0% (9/29)
2012^c	Yingjiang	3.9% (2/50)	100.0% (43/43)^a	0.0% (0/43)	0.0% (0/43)	0.0% (0/43)	14.0% (7/50)
2012^c	Tengchong	4.5% (1/22)	100.0% (20/20)	0.0% (0/20)	0.0% (0/20)	0.0% (0/20)	9.1% (2/22)
2013	Yingjiang	9.5% (2/22)	100.0% (20/20)	0.0% (0/20)	0.0% (0/20)	0.0% (0/20)	9.1% (2/22)
2013	Ruili	0.0% (0/11)	100.0% (6/6)	0.0% (0/6)	0.0% (0/6)	0.0% (0/6)	45.5% (5/11)
2014	Menglian	2.5% (1/40)	96.8% (30/31)	3.1% (1/31)^b	0.0% (0/31)	0.0% (0/31)	22.5% (9/40)

ACPR, adequate clinical parasitological response; LCF, late clinical failure; LPF, late parasitological failure; ETF, early treatment failure; WTH, withdrawal; LFU, loss to follow-up
^aOne of 43 participants had parasite and fever on day 3, but this case was continually followed up and cleared parasitaemia without rescue treatment and was finally classified to be ACPR
^bP. vivax infection was positive on day 35
^cPart data of the therapeutic efficacy study of DHA-PPQ has been presented in another study [7]

ISSN: 1475-2875